nodes	percent_of_prediction	percent_of_DWPC	metapath
Levobunolol—Rash generalised—Vemurafenib—melanoma	0.0654	0.0872	CcSEcCtD
Levobunolol—Cerebral ischaemia—Temozolomide—melanoma	0.0294	0.0392	CcSEcCtD
Levobunolol—Rash generalised—Docetaxel—melanoma	0.0222	0.0296	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Vemurafenib—melanoma	0.0154	0.0206	CcSEcCtD
Levobunolol—Respiratory failure—Temozolomide—melanoma	0.0145	0.0193	CcSEcCtD
Levobunolol—Erythema multiforme—Vemurafenib—melanoma	0.0132	0.0176	CcSEcCtD
Levobunolol—Cerebrovascular accident—Bleomycin—melanoma	0.0125	0.0166	CcSEcCtD
Levobunolol—Alopecia—Vemurafenib—melanoma	0.0123	0.0165	CcSEcCtD
Levobunolol—Diabetes mellitus—Carmustine—melanoma	0.0123	0.0164	CcSEcCtD
Levobunolol—Lethargy—Dactinomycin—melanoma	0.0116	0.0155	CcSEcCtD
Levobunolol—Nasal congestion—Temozolomide—melanoma	0.0113	0.0151	CcSEcCtD
Levobunolol—Diplopia—Carmustine—melanoma	0.0107	0.0142	CcSEcCtD
Levobunolol—Bronchospasm—Bleomycin—melanoma	0.0104	0.0139	CcSEcCtD
Levobunolol—Diplopia—Temozolomide—melanoma	0.0103	0.0138	CcSEcCtD
Levobunolol—Ataxia—Carmustine—melanoma	0.01	0.0134	CcSEcCtD
Levobunolol—Ataxia—Temozolomide—melanoma	0.0097	0.0129	CcSEcCtD
Levobunolol—Respiratory failure—Docetaxel—melanoma	0.00963	0.0128	CcSEcCtD
Levobunolol—Hypotension—Vemurafenib—melanoma	0.00927	0.0124	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Dactinomycin—melanoma	0.00872	0.0116	CcSEcCtD
Levobunolol—Erectile dysfunction—Temozolomide—melanoma	0.00822	0.0109	CcSEcCtD
Levobunolol—Depression—Carmustine—melanoma	0.00821	0.0109	CcSEcCtD
Levobunolol—Depression—Temozolomide—melanoma	0.00793	0.0106	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Temozolomide—melanoma	0.00788	0.0105	CcSEcCtD
Levobunolol—Cardiac failure congestive—Docetaxel—melanoma	0.00757	0.0101	CcSEcCtD
Levobunolol—Alopecia—Bleomycin—melanoma	0.00748	0.00997	CcSEcCtD
Levobunolol—Erythema multiforme—Dactinomycin—melanoma	0.00746	0.00995	CcSEcCtD
Levobunolol—Hypersensitivity—Vemurafenib—melanoma	0.00731	0.00974	CcSEcCtD
Levobunolol—Visual disturbance—Docetaxel—melanoma	0.00724	0.00965	CcSEcCtD
Levobunolol—Asthenia—Vemurafenib—melanoma	0.00712	0.00949	CcSEcCtD
Levobunolol—Visual impairment—Carmustine—melanoma	0.00712	0.00949	CcSEcCtD
Levobunolol—Pruritus—Vemurafenib—melanoma	0.00702	0.00936	CcSEcCtD
Levobunolol—Lethargy—Docetaxel—melanoma	0.007	0.00933	CcSEcCtD
Levobunolol—Alopecia—Dactinomycin—melanoma	0.00698	0.0093	CcSEcCtD
Levobunolol—Visual impairment—Temozolomide—melanoma	0.00688	0.00917	CcSEcCtD
Levobunolol—Diarrhoea—Vemurafenib—melanoma	0.00679	0.00905	CcSEcCtD
Levobunolol—Erythema multiforme—Temozolomide—melanoma	0.00675	0.009	CcSEcCtD
Levobunolol—Arrhythmia—Carmustine—melanoma	0.0066	0.00879	CcSEcCtD
Levobunolol—Dizziness—Vemurafenib—melanoma	0.00656	0.00875	CcSEcCtD
Levobunolol—Alopecia—Carmustine—melanoma	0.00653	0.0087	CcSEcCtD
Levobunolol—Ataxia—Docetaxel—melanoma	0.00645	0.0086	CcSEcCtD
Levobunolol—Alopecia—Temozolomide—melanoma	0.00631	0.00841	CcSEcCtD
Levobunolol—Chest pain—Bleomycin—melanoma	0.00627	0.00836	CcSEcCtD
Levobunolol—Headache—Vemurafenib—melanoma	0.00622	0.00829	CcSEcCtD
Levobunolol—Confusional state—Bleomycin—melanoma	0.00606	0.00808	CcSEcCtD
Levobunolol—Nausea—Vemurafenib—melanoma	0.0059	0.00786	CcSEcCtD
Levobunolol—Bronchospasm—Docetaxel—melanoma	0.00583	0.00778	CcSEcCtD
Levobunolol—Hypotension—Bleomycin—melanoma	0.00562	0.00749	CcSEcCtD
Levobunolol—Palpitations—Temozolomide—melanoma	0.00549	0.00732	CcSEcCtD
Levobunolol—Chest pain—Carmustine—melanoma	0.00548	0.0073	CcSEcCtD
Levobunolol—Paraesthesia—Bleomycin—melanoma	0.0054	0.0072	CcSEcCtD
Levobunolol—Dyspnoea—Bleomycin—melanoma	0.00536	0.00714	CcSEcCtD
Levobunolol—Confusional state—Carmustine—melanoma	0.00529	0.00705	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Docetaxel—melanoma	0.00524	0.00699	CcSEcCtD
Levobunolol—Pain—Bleomycin—melanoma	0.00514	0.00685	CcSEcCtD
Levobunolol—Conjunctivitis—Docetaxel—melanoma	0.00514	0.00685	CcSEcCtD
Levobunolol—Confusional state—Temozolomide—melanoma	0.00511	0.00682	CcSEcCtD
Levobunolol—Feeling abnormal—Bleomycin—melanoma	0.00496	0.0066	CcSEcCtD
Levobunolol—Hypotension—Carmustine—melanoma	0.0049	0.00654	CcSEcCtD
Levobunolol—Pain—Dactinomycin—melanoma	0.0048	0.00639	CcSEcCtD
Levobunolol—Urticaria—Bleomycin—melanoma	0.00478	0.00637	CcSEcCtD
Levobunolol—Paraesthesia—Carmustine—melanoma	0.00471	0.00628	CcSEcCtD
Levobunolol—Dyspnoea—Carmustine—melanoma	0.00468	0.00624	CcSEcCtD
Levobunolol—Feeling abnormal—Dactinomycin—melanoma	0.00462	0.00616	CcSEcCtD
Levobunolol—Visual impairment—Docetaxel—melanoma	0.00458	0.0061	CcSEcCtD
Levobunolol—Paraesthesia—Temozolomide—melanoma	0.00455	0.00607	CcSEcCtD
Levobunolol—Dyspnoea—Temozolomide—melanoma	0.00452	0.00603	CcSEcCtD
Levobunolol—Erythema multiforme—Docetaxel—melanoma	0.00449	0.00598	CcSEcCtD
Levobunolol—Pain—Carmustine—melanoma	0.00449	0.00598	CcSEcCtD
Levobunolol—Hypersensitivity—Bleomycin—melanoma	0.00443	0.0059	CcSEcCtD
Levobunolol—Pain—Temozolomide—melanoma	0.00434	0.00578	CcSEcCtD
Levobunolol—Feeling abnormal—Carmustine—melanoma	0.00433	0.00576	CcSEcCtD
Levobunolol—Asthenia—Bleomycin—melanoma	0.00431	0.00575	CcSEcCtD
Levobunolol—Pruritus—Bleomycin—melanoma	0.00425	0.00567	CcSEcCtD
Levobunolol—Arrhythmia—Docetaxel—melanoma	0.00424	0.00565	CcSEcCtD
Levobunolol—Alopecia—Docetaxel—melanoma	0.0042	0.00559	CcSEcCtD
Levobunolol—Feeling abnormal—Temozolomide—melanoma	0.00418	0.00557	CcSEcCtD
Levobunolol—Hypersensitivity—Dactinomycin—melanoma	0.00413	0.00551	CcSEcCtD
Levobunolol—Urticaria—Temozolomide—melanoma	0.00403	0.00537	CcSEcCtD
Levobunolol—Asthenia—Dactinomycin—melanoma	0.00402	0.00536	CcSEcCtD
Levobunolol—Hypersensitivity—Carmustine—melanoma	0.00387	0.00515	CcSEcCtD
Levobunolol—Diarrhoea—Dactinomycin—melanoma	0.00384	0.00511	CcSEcCtD
Levobunolol—Asthenia—Carmustine—melanoma	0.00377	0.00502	CcSEcCtD
Levobunolol—Hypersensitivity—Temozolomide—melanoma	0.00374	0.00498	CcSEcCtD
Levobunolol—Syncope—Docetaxel—melanoma	0.00371	0.00494	CcSEcCtD
Levobunolol—Palpitations—Docetaxel—melanoma	0.00365	0.00487	CcSEcCtD
Levobunolol—Asthenia—Temozolomide—melanoma	0.00364	0.00485	CcSEcCtD
Levobunolol—Loss of consciousness—Docetaxel—melanoma	0.00363	0.00484	CcSEcCtD
Levobunolol—Diarrhoea—Carmustine—melanoma	0.00359	0.00479	CcSEcCtD
Levobunolol—Pruritus—Temozolomide—melanoma	0.00359	0.00478	CcSEcCtD
Levobunolol—Nausea—Bleomycin—melanoma	0.00357	0.00476	CcSEcCtD
Levobunolol—Chest pain—Docetaxel—melanoma	0.00352	0.00469	CcSEcCtD
Levobunolol—Dizziness—Carmustine—melanoma	0.00347	0.00463	CcSEcCtD
Levobunolol—Diarrhoea—Temozolomide—melanoma	0.00347	0.00462	CcSEcCtD
Levobunolol—Confusional state—Docetaxel—melanoma	0.0034	0.00453	CcSEcCtD
Levobunolol—Dizziness—Temozolomide—melanoma	0.00335	0.00447	CcSEcCtD
Levobunolol—Nausea—Dactinomycin—melanoma	0.00333	0.00444	CcSEcCtD
Levobunolol—Shock—Docetaxel—melanoma	0.00332	0.00442	CcSEcCtD
Levobunolol—Headache—Carmustine—melanoma	0.00329	0.00438	CcSEcCtD
Levobunolol—Headache—Temozolomide—melanoma	0.00318	0.00423	CcSEcCtD
Levobunolol—Hypotension—Docetaxel—melanoma	0.00315	0.0042	CcSEcCtD
Levobunolol—Nausea—Carmustine—melanoma	0.00312	0.00415	CcSEcCtD
Levobunolol—Paraesthesia—Docetaxel—melanoma	0.00303	0.00404	CcSEcCtD
Levobunolol—Nausea—Temozolomide—melanoma	0.00301	0.00401	CcSEcCtD
Levobunolol—Dyspnoea—Docetaxel—melanoma	0.00301	0.00401	CcSEcCtD
Levobunolol—Pain—Docetaxel—melanoma	0.00288	0.00384	CcSEcCtD
Levobunolol—Feeling abnormal—Docetaxel—melanoma	0.00278	0.0037	CcSEcCtD
Levobunolol—Timolol—ABCB1—melanoma	0.00264	0.484	CrCbGaD
Levobunolol—Hypersensitivity—Docetaxel—melanoma	0.00249	0.00331	CcSEcCtD
Levobunolol—Asthenia—Docetaxel—melanoma	0.00242	0.00323	CcSEcCtD
Levobunolol—Pruritus—Docetaxel—melanoma	0.00239	0.00318	CcSEcCtD
Levobunolol—Diarrhoea—Docetaxel—melanoma	0.00231	0.00308	CcSEcCtD
Levobunolol—Dizziness—Docetaxel—melanoma	0.00223	0.00297	CcSEcCtD
Levobunolol—Headache—Docetaxel—melanoma	0.00211	0.00282	CcSEcCtD
Levobunolol—Nadolol—ABCB1—melanoma	0.0021	0.384	CrCbGaD
Levobunolol—Nausea—Docetaxel—melanoma	0.002	0.00267	CcSEcCtD
Levobunolol—Propranolol—ABCB1—melanoma	0.000719	0.132	CrCbGaD
Levobunolol—ADRB2—Signaling Pathways—GRM3—melanoma	0.000301	0.00123	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—GNAQ—melanoma	0.000298	0.00122	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—CXCR4—melanoma	0.000294	0.00121	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—KISS1—melanoma	0.000291	0.00119	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—GNAQ—melanoma	0.000291	0.00119	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—GNA11—melanoma	0.000291	0.00119	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—GAB2—melanoma	0.000291	0.00119	CbGpPWpGaD
Levobunolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—melanoma	0.00029	0.00119	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—KISS1—melanoma	0.000285	0.00117	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—GNA11—melanoma	0.000284	0.00116	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—GAB2—melanoma	0.000284	0.00116	CbGpPWpGaD
Levobunolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—melanoma	0.000283	0.00116	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CXCR1—melanoma	0.000282	0.00116	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SKI—melanoma	0.000282	0.00116	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MC1R—melanoma	0.000278	0.00114	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SKI—melanoma	0.000276	0.00113	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CXCR1—melanoma	0.000276	0.00113	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—AKT3—melanoma	0.000275	0.00112	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CXCR4—melanoma	0.000273	0.00112	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MC1R—melanoma	0.000272	0.00111	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—GNAQ—melanoma	0.00027	0.00111	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—AKT3—melanoma	0.000269	0.0011	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CXCR4—melanoma	0.000267	0.00109	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—GRM1—melanoma	0.000266	0.00109	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CCR7—melanoma	0.000266	0.00109	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—GNAQ—melanoma	0.000264	0.00108	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—GRM1—melanoma	0.000261	0.00107	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CCR7—melanoma	0.000261	0.00107	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SUFU—melanoma	0.00026	0.00106	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SUFU—melanoma	0.000254	0.00104	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—AKT3—melanoma	0.000249	0.00102	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—AKT3—melanoma	0.000244	0.000999	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—BCL2L11—melanoma	0.000242	0.000993	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—RHOB—melanoma	0.000242	0.000993	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—BCL2L11—melanoma	0.000237	0.000971	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—RHOB—melanoma	0.000237	0.000971	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—HDAC6—melanoma	0.000233	0.000954	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—EDN1—melanoma	0.000231	0.000945	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—HDAC6—melanoma	0.000228	0.000933	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—EDN1—melanoma	0.000226	0.000924	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—CSF2—melanoma	0.000225	0.000924	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CXCR2—melanoma	0.000221	0.000904	CbGpPWpGaD
Levobunolol—ADRB1—GPCR ligand binding—CXCL8—melanoma	0.000221	0.000904	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—CSF2—melanoma	0.000221	0.000904	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—RAC2—melanoma	0.000217	0.00089	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PRKCA—melanoma	0.000216	0.000886	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CXCR2—melanoma	0.000216	0.000885	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—CXCL8—melanoma	0.000216	0.000884	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—WNT5A—melanoma	0.000214	0.000876	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—VEGFC—melanoma	0.000214	0.000876	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—RAC2—melanoma	0.000212	0.00087	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PRKCA—melanoma	0.000211	0.000866	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—EDN1—melanoma	0.000209	0.000858	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—VEGFC—melanoma	0.000209	0.000857	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—WNT5A—melanoma	0.000209	0.000857	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—EDN1—melanoma	0.000205	0.000839	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CSF2—melanoma	0.000205	0.000839	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—RAC1—melanoma	0.0002	0.000821	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CSF2—melanoma	0.0002	0.00082	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PRKCA—melanoma	0.000196	0.000804	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—RAC1—melanoma	0.000196	0.000803	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PRKCA—melanoma	0.000192	0.000787	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—MAP2K2—melanoma	0.000192	0.000786	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—MAP2K2—melanoma	0.000188	0.000769	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—F2R—melanoma	0.000188	0.000769	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—F2R—melanoma	0.000184	0.000752	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—RAC1—melanoma	0.000182	0.000746	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—EDNRB—melanoma	0.000182	0.000745	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—RAC1—melanoma	0.000178	0.000729	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—EDNRB—melanoma	0.000178	0.000728	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PTK2B—melanoma	0.000176	0.000723	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PTK2B—melanoma	0.000173	0.000707	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—GAB2—melanoma	0.000172	0.000703	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—GNA11—melanoma	0.000172	0.000703	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—FLT1—melanoma	0.000171	0.0007	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PIK3CG—melanoma	0.000169	0.000694	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—GAB2—melanoma	0.000168	0.000688	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—GNA11—melanoma	0.000168	0.000688	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—FLT1—melanoma	0.000167	0.000685	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PIK3CG—melanoma	0.000166	0.000678	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—FOXO4—melanoma	0.000161	0.000661	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—HDAC2—melanoma	0.000161	0.000661	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CXCR4—melanoma	0.000161	0.000661	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—GNAQ—melanoma	0.00016	0.000654	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—FOXO4—melanoma	0.000158	0.000647	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CXCR4—melanoma	0.000158	0.000647	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—HDAC2—melanoma	0.000158	0.000647	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—GNAQ—melanoma	0.000156	0.00064	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PIK3CG—melanoma	0.000154	0.00063	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PIK3CG—melanoma	0.00015	0.000616	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SYK—melanoma	0.00015	0.000615	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PIK3CD—melanoma	0.000149	0.00061	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—AKT3—melanoma	0.000147	0.000603	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—NGFR—melanoma	0.000147	0.000603	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—ITGAV—melanoma	0.000147	0.000603	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SYK—melanoma	0.000147	0.000601	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PIK3CD—melanoma	0.000146	0.000596	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—NGFR—melanoma	0.000144	0.00059	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—ITGAV—melanoma	0.000144	0.00059	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—AKT3—melanoma	0.000144	0.00059	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SOCS1—melanoma	0.000136	0.000559	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—MAP2K1—melanoma	0.000136	0.000557	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—S100B—melanoma	0.000136	0.000557	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PIK3CD—melanoma	0.000135	0.000554	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SOCS1—melanoma	0.000133	0.000547	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—MAP2K1—melanoma	0.000133	0.000545	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—S100B—melanoma	0.000133	0.000545	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PIK3CD—melanoma	0.000132	0.000542	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—ERBB4—melanoma	0.00013	0.000533	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PIK3CB—melanoma	0.00013	0.000531	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CDKN2B—melanoma	0.000129	0.000528	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—ERBB4—melanoma	0.000127	0.000521	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PIK3CB—melanoma	0.000127	0.00052	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CDKN2B—melanoma	0.000126	0.000517	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CD86—melanoma	0.000125	0.000511	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—CXCL8—melanoma	0.000125	0.000511	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—EDN1—melanoma	0.000124	0.000507	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CD86—melanoma	0.000122	0.0005	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—CXCL8—melanoma	0.000122	0.0005	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—EDN1—melanoma	0.000121	0.000496	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CSF2—melanoma	0.000121	0.000495	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—FGF1—melanoma	0.000121	0.000495	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—IL2—melanoma	0.000119	0.000488	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—E2F1—melanoma	0.000118	0.000485	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CSF2—melanoma	0.000118	0.000485	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—FGF1—melanoma	0.000118	0.000485	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PIK3CB—melanoma	0.000118	0.000483	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PDGFRA—melanoma	0.000117	0.00048	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—IL2—melanoma	0.000117	0.000477	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—ITGB3—melanoma	0.000116	0.000475	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PRKCA—melanoma	0.000116	0.000475	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—E2F1—melanoma	0.000116	0.000474	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PIK3CB—melanoma	0.000115	0.000472	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PDGFRA—melanoma	0.000115	0.000469	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SPP1—melanoma	0.000114	0.000466	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—ITGB3—melanoma	0.000113	0.000465	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PRKCA—melanoma	0.000113	0.000465	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MAP2K2—melanoma	0.000113	0.000464	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CXCL8—melanoma	0.000113	0.000464	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SPP1—melanoma	0.000111	0.000456	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MAP2K2—melanoma	0.000111	0.000454	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CXCL8—melanoma	0.000111	0.000454	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—IL2—melanoma	0.000108	0.000443	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—TERT—melanoma	0.000108	0.000442	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—RAC1—melanoma	0.000108	0.00044	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—IL2—melanoma	0.000106	0.000434	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—TERT—melanoma	0.000105	0.000432	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—RAC1—melanoma	0.000105	0.000431	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—HIF1A—melanoma	0.000103	0.000422	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—HIF1A—melanoma	0.000101	0.000413	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—KDR—melanoma	9.86e-05	0.000404	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—KDR—melanoma	9.65e-05	0.000395	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—FN1—melanoma	9.49e-05	0.000389	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—NOTCH1—melanoma	9.29e-05	0.00038	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—FN1—melanoma	9.28e-05	0.00038	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CD80—melanoma	9.1e-05	0.000373	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—NOTCH1—melanoma	9.09e-05	0.000372	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—KIT—melanoma	9.08e-05	0.000372	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PIK3CG—melanoma	9.08e-05	0.000372	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—APC—melanoma	9.08e-05	0.000372	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—NRAS—melanoma	9.08e-05	0.000372	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—EGF—melanoma	8.98e-05	0.000368	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CD80—melanoma	8.9e-05	0.000365	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PIK3CG—melanoma	8.89e-05	0.000364	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—APC—melanoma	8.89e-05	0.000364	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—KIT—melanoma	8.89e-05	0.000364	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—NRAS—melanoma	8.89e-05	0.000364	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—EGF—melanoma	8.78e-05	0.00036	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—MAPK3—melanoma	8.7e-05	0.000356	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—BRAF—melanoma	8.54e-05	0.00035	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—MAPK3—melanoma	8.51e-05	0.000349	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—BRAF—melanoma	8.35e-05	0.000342	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—IGF1—melanoma	8.32e-05	0.000341	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—MAPK1—melanoma	8.28e-05	0.000339	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—EGFR—melanoma	8.28e-05	0.000339	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—IGF1—melanoma	8.14e-05	0.000333	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—MAPK1—melanoma	8.1e-05	0.000332	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—EGFR—melanoma	8.1e-05	0.000332	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MAP2K1—melanoma	8.04e-05	0.000329	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PIK3CD—melanoma	7.98e-05	0.000327	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PIK3CA—melanoma	7.91e-05	0.000324	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MAP2K1—melanoma	7.86e-05	0.000322	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—KRAS—melanoma	7.82e-05	0.00032	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PIK3CD—melanoma	7.81e-05	0.00032	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PIK3CA—melanoma	7.74e-05	0.000317	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—KRAS—melanoma	7.65e-05	0.000313	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—FGF2—melanoma	7.65e-05	0.000313	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—FGF2—melanoma	7.48e-05	0.000306	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PIK3CA—melanoma	7.18e-05	0.000294	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MDM2—melanoma	7.15e-05	0.000293	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—ERBB2—melanoma	7.05e-05	0.000289	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PIK3CA—melanoma	7.03e-05	0.000288	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MDM2—melanoma	7e-05	0.000287	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PIK3CB—melanoma	6.96e-05	0.000285	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—ERBB2—melanoma	6.9e-05	0.000283	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PIK3CB—melanoma	6.81e-05	0.000279	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CXCL8—melanoma	6.69e-05	0.000274	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—HRAS—melanoma	6.64e-05	0.000272	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CXCL8—melanoma	6.54e-05	0.000268	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CDKN1B—melanoma	6.53e-05	0.000268	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—HRAS—melanoma	6.5e-05	0.000266	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—AKT1—melanoma	6.46e-05	0.000265	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CASP3—melanoma	6.4e-05	0.000262	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—IL2—melanoma	6.39e-05	0.000262	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CDKN1B—melanoma	6.39e-05	0.000262	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—IL6—melanoma	6.36e-05	0.000261	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—AKT1—melanoma	6.32e-05	0.000259	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CASP3—melanoma	6.26e-05	0.000257	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—IL2—melanoma	6.25e-05	0.000256	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CCND1—melanoma	6.23e-05	0.000255	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—IL6—melanoma	6.22e-05	0.000255	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CTNNB1—melanoma	6.17e-05	0.000253	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CCND1—melanoma	6.1e-05	0.00025	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MMP9—melanoma	6.05e-05	0.000248	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CTNNB1—melanoma	6.04e-05	0.000247	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CDKN1A—melanoma	6.03e-05	0.000247	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PTEN—melanoma	6.01e-05	0.000246	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—NFKB1—melanoma	5.99e-05	0.000245	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MMP9—melanoma	5.92e-05	0.000242	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CDKN1A—melanoma	5.9e-05	0.000242	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PTEN—melanoma	5.88e-05	0.000241	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—AKT1—melanoma	5.87e-05	0.00024	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—NFKB1—melanoma	5.85e-05	0.00024	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—AKT1—melanoma	5.74e-05	0.000235	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—VEGFA—melanoma	5.43e-05	0.000223	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—STAT3—melanoma	5.38e-05	0.00022	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—NRAS—melanoma	5.37e-05	0.00022	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—VEGFA—melanoma	5.31e-05	0.000218	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—STAT3—melanoma	5.26e-05	0.000216	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—NRAS—melanoma	5.25e-05	0.000215	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MAPK3—melanoma	5.14e-05	0.000211	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MAPK3—melanoma	5.03e-05	0.000206	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MYC—melanoma	5e-05	0.000205	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MAPK1—melanoma	4.89e-05	0.0002	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MYC—melanoma	4.89e-05	0.0002	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—EGFR—melanoma	4.89e-05	0.0002	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MAPK1—melanoma	4.78e-05	0.000196	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—EGFR—melanoma	4.78e-05	0.000196	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—KRAS—melanoma	4.62e-05	0.000189	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—KRAS—melanoma	4.52e-05	0.000185	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PIK3CA—melanoma	4.24e-05	0.000174	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PIK3CA—melanoma	4.15e-05	0.00017	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—TP53—melanoma	4.1e-05	0.000168	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—TP53—melanoma	4.02e-05	0.000164	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—HRAS—melanoma	3.93e-05	0.000161	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—HRAS—melanoma	3.84e-05	0.000157	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—IL6—melanoma	3.76e-05	0.000154	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—IL6—melanoma	3.68e-05	0.000151	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—AKT1—melanoma	3.47e-05	0.000142	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—AKT1—melanoma	3.39e-05	0.000139	CbGpPWpGaD
